{
    "organizations": [],
    "uuid": "31323b3111fc576d46b1d87f131fd1989084d529",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-zymeworks-and-daiichi-sankyo-expan/brief-zymeworks-and-daiichi-sankyo-expand-immuno-oncology-collaboration-focused-on-bispecific-antibodies-idUSFWN1SL15D",
    "ord_in_thread": 0,
    "title": "BRIEF-Zymeworks And Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused On Bispecific Antibodies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 14 (Reuters) - Daiichi Sankyo Co Ltd:\n* ZYMEWORKS AND DAIICHI SANKYO EXPAND IMMUNO-ONCOLOGY COLLABORATION FOCUSED ON BISPECIFIC ANTIBODIES\n* ZYMEWORKS- TO GET UPFRONT TECHNOLOGY ACCESS FEE OF $18 MILLION; MAY GET UP TO $466.7 MILLION IN POTENTIAL CLINICAL, REGULATORY, COMMERCIAL MILESTONE PAYMENTS\n* ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE UP TO DOUBLE-DIGIT TIERED ROYALTIES ON GLOBAL PRODUCT SALES\n* ZYMEWORKS - DAIICHI SANKYO TO ACQUIRE LICENSES TO COâ€™S AZYMETRIC AND EFECT TECHNOLOGY PLATFORMS TO DEVELOP 2 ADDITIONAL BISPECIFIC ANTIBODY THERAPEUTICS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-15T05:13:00.000+03:00",
    "crawled": "2018-05-15T14:18:23.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "daiichi",
        "sankyo",
        "co",
        "ltd",
        "zymeworks",
        "daiichi",
        "sankyo",
        "expand",
        "collaboration",
        "focused",
        "bispecific",
        "antibody",
        "get",
        "upfront",
        "technology",
        "access",
        "fee",
        "million",
        "may",
        "get",
        "million",
        "potential",
        "clinical",
        "regulatory",
        "commercial",
        "milestone",
        "payment",
        "zymeworks",
        "inc",
        "zymeworks",
        "receive",
        "tiered",
        "royalty",
        "global",
        "product",
        "sale",
        "zymeworks",
        "daiichi",
        "sankyo",
        "acquire",
        "license",
        "co",
        "azymetric",
        "efect",
        "technology",
        "platform",
        "develop",
        "additional",
        "bispecific",
        "antibody",
        "therapeutic",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}